| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-07 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.18 | 8e-07 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-06 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-06 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.24 | 6e-06 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.24 | 7e-06 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | -0.16 | 4e-05 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.14 | 7e-05 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.15 | 9e-05 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0001 |